Novel pharmacological chaperones that correct phenylketonuria in mice

Human Molecular Genetics

Volumn 21, Issue 8, 2012, Pages 1877-1887

  Santos sierra, Sandra ^a   Kirchmair, Johannes ^b   Perna, Anna M ^b   Reiß, Dunja ^c   Kemter, Kristina ^c   R̈schinger, Wulf ^d   Glossmann, Hartmut ^e   Gersting, Søren W ^c   Muntau, Ania C ^c   Wolber, Gerhard ^b   Lagler, Florian B ^a,f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Becker and Colleagues Laboratory   (Germany)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3,5,6,7 TETRAHYDRO 6,7 DIHYDROXY 6 METHYL 9H IMIDAZO[1,2 A]PURIN 9 ONE; 5 BENZYLHYDANTOIN; 5 BENZYLIDENE 2 THIOHYDANTOIN; 5 FURFURYLHYDANTOIN; 6 AMINO 5 (BENZYLAMINO)URACIL; 8 PHENYLGUANINE; CHAPERONE; PHENYLALANINE 4 MONOOXYGENASE; TETRAHYDROBIOPTERIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATH ANALYSIS; CELL VIABILITY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATION; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; SURFACE PLASMON RESONANCE;

ANIMALS; BINDING SITES; BIOPTERIN; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME STABILITY; HUMANS; HYDANTOINS; MICE; OXIDATION-REDUCTION; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; PROTEIN FOLDING; SMALL MOLECULE LIBRARIES; URACIL;

MUS;

EID: 84859261141     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds001     Document Type: Article

References (70)

1. Donlon, K., Levy, H. and Scriver, C.R. (2007) Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Childs, B. and Kinzler, K.W. (eds), The Metabolic & Molecular Bases of Inherited Disease. McGraw-Hill, New York.
2. Enns, G.M., Koch, R., Brumm, V., Blakely, E., Suter, R. and Jurecki, E. (2010) Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol. Genet. Metab., 101, 99-109.
3. Smith, I. and Knowles, J. (2000) Behaviour in early treated phenylketonuria: a systematic review. Eur. J. Pediatr., 159(Suppl. 2), S89-S93.
4. Panel, N.C.D. (2001) National Institutes of Health Consensus Development Conference Statement. Phenylketonuria: screening and management October 16-18, 2000. Pediatrics, 108, 972-982.
5. Guttler, F. and Lou, H. (1986) Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J. Inherit. Metab. Dis., 9(Suppl. 2), 169-177.
6. Matalon, R., Michals-Matalon, K., Bhatia, G., Burlina, A.B., Burlina, A.P., Braga, C., Fiori, L., Giovannini, M., Grechanina, E., Novikov, P. et al. (2007) Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J. Inherit. Metab. Dis., 30, 153-158.
7. Pietz, J., Kreis, R., Rupp, A., Mayatepek, E., Rating, D., Boesch, C. and Bremer, H.J. (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J. Clin. Invest., 103, 1169-1178.
8. Sarkissian, C.N., Kang, T.S., Gamez, A., Scriver, C.R. and Stevens, R.C. (2011) Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria. Mol. Genet. Metab., 104, 249-254.
9. Sarkissian, C.N., Gamez, A., Wang, L., Charbonneau, M., Fitzpatrick, P., Lemontt, J.F., Zhao, B., Vellard, M., Bell, S.M., Henschell, C. et al. (2008) Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl Acad. Sci. USA, 105, 20894-20899.
10. MacDonald, M.J. and D'Cunha, G.B. (2007) A modern view of phenylalanine ammonia lyase. Biochem. Cell Biol., 85, 273-282.
11. Rebuffat, A., Harding, C.O., Ding, Z. and Thony, B. (2010) Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum. Gene Ther., 21, 463-477.
12. Ding, Z., Harding, C.O., Rebuffat, A., Elzaouk, L., Wolff, J.A. and Thony, B. (2008) Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol. Ther., 16, 673-681.
13. van Spronsen, F.J. and Enns, G.M. (2010) Future treatment strategies in phenylketonuria. Mol. Genet. Metab., 99(Suppl. 1), S90-S95.
14. Kure, S., Hou, D.C., Ohura, T., Iwamoto, H., Suzuki, S., Sugiyama, N., Sakamoto, O., Fujii, K., Matsubara, Y. and Narisawa, K. (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr., 135, 375-378.
15. Muntau, A.C., Röschinger, W., Habich, M., Demmelmair, H., Hoffmann, B., Sommerhoff, C.P. and Roscher, A.A. (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med., 347, 2122-2132.
16. Bernegger, C. and Blau, N. (2002) High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol. Genet. Metab., 77, 304-313.
17. Erlandsen, H., Pey, A.L., Gámez, A., Pérez, B., Desviat, L.R., Aguado, C., Koch, R., Surendran, S., Tyring, S., Matalon, R. et al. (2004) Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc. Natl Acad. Sci. USA, 101, 16903-16908.
18. Steinfeld, R., Kohlschütter, A., Zschocke, J., Lindner, M., Ullrich, K. and Lukacs, Z. (2002) Tetrahydrobiopterin monotherapy for phenylketonuria patients with common mild mutations. Eur. J. Pediatr., 161, 403-405.
19. Wang, L., Surendran, S., Michals-Matalon, K., Bhatia, G., Tanskley, S., Koch, R., Grady, J., Tyring, S.K., Stevens, R.C., Güttler, F. et al. (2007) Mutations in the regulatory domain of phenylalanine hydroxylase and response to tetrahydrobiopterin. Genet. Test, 11, 174-178.
20. FDA. U.S.F.a.D.A. KUVAN, NDA no. 022181. US: Food and Drug Administration (FDA), Silver Spring, MD, Vol. 2011. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Label_ApprovalHistory.
21. Aguado, C., Pérez, B., Ugarte, M. and Desviat, L.R. (2006) Analysis of the effect of tetrahydrobiopterin on PAH gene expression in hepatoma cells. FEBS Lett., 580, 1697-1701.
22. Gersting, S.W., Lagler, F.B., Eichinger, A., Kemter, K.F., Danecka, M.K., Messing, D.D., Staudigl, M., Domdey, K.A., Zsifkovits, C., Fingerhut, R. et al. (2010) Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum. Mol. Genet., 19, 2039-2049.
23. Shiman, R., Jones, S.H. and Gray, D.W. (1990) Mechanism of phenylalanine regulation of phenylalanine hydroxylase. J. Biol. Chem., 265, 11633-11642.
24. Erlandsen, H., Patch, M.G., Gámez, A., Straub, M. and Stevens, R.C. (2003) Structural studies on phenylalanine hydroxylase and implications toward understanding and treating phenylketonuria. Pediatrics, 112, 1557-1565.
25. Kappock, T.J. and Caradonna, J.P. (1996) Pterin-dependent amino acid hydroxylases. Chem. Rev., 96, 2659-2756.
26. Phillips, R.S. and Kaufman, S. (1984) Ligand effects on the phosphorylation state of hepatic phenylalanine hydroxylase. J. Biol. Chem., 259, 2474-2479.
27. Solstad, T., Stokka, A.J., Andersen, O.A. and Flatmark, T. (2003) Studies on the regulatory properties of the pterin cofactor and dopamine bound at the active site of human phenylalanine hydroxylase. Eur. J. Biochem., 270, 981-990.
28. Kirchmair, J., Distinto, S., Liedl, K.R., Markt, P., Rollinger, J.M., Schuster, D., Spitzer, G.M. and Wolber, G. (2010) Development of anti-viral agents using molecular modeling and virtual screening techniques. Infect. Disord. Drug Targets, 11, 64-93.
29. Rollinger, J.M., Stuppner, H. and Langer, T. (2008) Virtual screening for the discovery of bioactive natural products. Prog. Drug Res., 65, 211, 213-249.
30. McDonald, J.D., Bode, V.C., Dove, W.F. and Shedlovsky, A. (1990) The use of N-ethyl-N-nitrosourea to produce mouse models for human phenylketonuria and hyperphenylalaninemia. Prog. Clin. Biol. Res., 340C, 407-413.
31. Shedlovsky, A., McDonald, J.D., Symula, D. and Dove, W.F. (1993) Mouse models of human phenylketonuria. Genetics, 134, 1205-1210.
32. Thöny, B., Ding, Z. and Martínez, A. (2004) Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: implications for tetrahydrobiopterin-responsive hyperphenylalaninemia. FEBS Lett., 577, 507-511.
33. Scavelli, R., Ding, Z., Blau, N., Haavik, J., Martínez, A. and Thöny, B. (2005) Stimulation of hepatic phenylalanine hydroxylase activity but not Pah-mRNA expression upon oral loading of tetrahydrobiopterin in normal mice. Mol. Genet. Metab., 86(Suppl. 1), S153-S155.
34. Sarkissian, C.N., Boulais, D.M., McDonald, J.D. and Scriver, C.R. (2000) A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia. Mol. Genet. Metab., 69, 188-194.
35. Maynard, J.A., Lindquist, N.C., Sutherland, J.N., Lesuffleur, A., Warrington, A.E., Rodriguez, M. and Oh, S.H. (2009) Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol. J., 4, 1542-1558.
36. Boscott, R.J. and Bickel, H. (1953) Detection of some new abnormal metabolites in the urine of phenylketonuria. Scand. J. Clin. Lab. Invest., 5, 380-382.
37. DeGraw, J.I., Cory, M., Skinner, W.A., Theisen, M.C. and Mitoma, C. (1967) Experimentally induced phenylketonuria. I. Inhibitors of phenylalanine hydroxylase. J. Med. Chem., 10, 64-66.
38. Bailey, S.W. and Ayling, J.E. (1978) Pyrimidines as cofactors for phenylalanine hydroxylase. Biochem. Biophys. Res. Commun., 85, 1614-1621.
39. Bailey, S.W. and Ayling, J.E. (1980) Cleavage of the 5-amino substituent of pyrimidine cofactors by phenylalanine hydroxylase. J. Biol. Chem., 255, 7774-7781.
40. Bailey, S.W., Weintraub, S.T., Hamilton, S.M. and Ayling, J.E. (1982) Incorporation of molecular oxygen into pyrimidine cofactors by phenylalanine hydroxylase. J. Biol. Chem., 257, 8253-8260.
41. Jongejan, J.A., Mager, H.I.X. and Berends, W. (1983) Pyrimidine models for the cofactor of phenylalanine hydroxylase. Autoxidation of 2,4,5-triamino-6-hydroxypyrimidines. In Blair, J.A. (ed.), Chemistry and Biology of Pteridines: Pteridines and Folic Acid Derivatives: Proceedings of the Seventh International Symposium on Pteridines and Folic Acid Derivatives, Chemical, Biological, and Clinical Aspects, St Andrews, Scotland, September 21-24, 1982. W. de Gruyter, pp. 357-361.
42. De Crescenzo, G., Grothe, S., Lortie, R., Debanne, M.T. and O'Connor-McCourt, M. (2000) Real-time kinetic studies on the interaction of transforming growth factor alpha with the epidermal growth factor receptor extracellular domain reveal a conformational change model. Biochemistry, 39, 9466-9476.
43. Knappskog, P.M. and Haavik, J. (1995) Tryptophan fluorescence of human phenylalanine hydroxylase produced in Escherichia coli. Biochemistry, 34, 11790-11799.
44. Thórólfsson, M., Teigen, K. and Martínez, A. (2003) Activation of phenylalanine hydroxylase: effect of substitutions at Arg68 and Cys237. Biochemistry, 42, 3419-3428.
45. Sarkissian, C.N., McDonald, J.D. and Curators, P. (2009) The Mouse Genetic PKU Model Home Page. http://www.pahdb.mcgill.ca/?Topic=Information&Section=Mouse&Page=0.
46. Lagler, F.B., Gersting, S.W., Zsifkovits, C., Steinbacher, A., Eichinger, A., Danecka, M.K., Staudigl, M., Fingerhut, R., Glossmann, H. and Muntau, A.C. (2010) New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Biochem. Pharmacol., 80, 1563-1571.
47. Treacy, E.P., Delente, J.J., Elkas, G., Carter, K., Lambert, M., Waters, P.J. and Scriver, C.R. (1997) Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using L-[1-13C]phenylalanine oxidation rates in vivo: a pilot study. Pediatr. Res., 42, 430-435.
48. Choi, S., Sainz, B. Jr., Corcoran, P., Uprichard, S. and Jeong, H. (2009) Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica, 39, 205-217.
49. Kim, S.J., Jung, Y.S., Yoon, M.Y. and Kim, Y.C. (2007) Comparative effects of dimethylsulfoxide on metabolism and toxicity of carbon tetrachloride and dichloromethane. J. Appl. Toxicol., 27, 25-31.
50. Horsley, W. (2009) Sapropterin (Kuvan®) in the Management of Phenylketonuria. National Health Service. http://www.netag.nhs.uk/files/appraisal-reports.
51. Jurecki, E. (2008) BioMarin's Kuvan is First FDA-Approved Drug for PKU. PKU news, 20, 1-3.
52. Feillet, F., van Spronsen, F.J., MacDonald, A., Trefz, F.K., Demirkol, M., Giovannini, M., Belanger-Quintana, A. and Blau, N. (2010) Challenges and pitfalls in the management of phenylketonuria. Pediatrics, 126, 333-341.
53. Staudigl, M., Gersting, S.W., Danecka, M.K., Messing, D.D., Woidy, M., Pinkas, D., Kemter, K.F., Blau, N. and Muntau, A.C. (2011) The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. Hum. Mol. Genet., 20, 2628-2641.
54. Pey, A.L., Ying, M., Cremades, N., Velázquez-Campoy, A., Scherer, T., Thöny, B., Sancho, J. and Martínez, A. (2008) Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Invest., 118, 2858-2867.
55. Shanmuganathan, M. and Britz-McKibbin, P. (2011) Inhibitor screening of pharmacological chaperones for lysosomal beta-glucocerebrosidase by capillary electrophoresis. Anal. Bioanal. Chem., 399, 2843-2853.
56. Tropak, M.B., Blanchard, J.E., Withers, S.G., Brown, E.D. and Mahuran, D. (2007) High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem. Biol., 14, 153-164.
57. Fan, J.Q. and Ishii, S. (2007) Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J., 274, 4962-4971.
58. Fan, J.Q. (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol. Sci., 24, 355-360.
59. Flatmark, T., Stokka, A.J. and Berge, S.V. (2001) Use of surface plasmon resonance for real-time measurements of the global conformational transition in human phenylalanine hydroxylase in response to substrate binding and catalytic activation. Anal. Biochem., 294, 95-101.
60. Gersting, S.W., Staudigl, M., Truger, M.S., Messing, D.D., Danecka, M.K., Sommerhoff, C.P., Kemter, K.F. and Muntau, A.C. (2010) Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor. J. Biol. Chem., 285, 30686-30697.
61. Okano, Y., Kudo, S., Nishi, Y., Sakaguchi, T. and Aso, K. (2011) Molecular characterization of phenylketonuria and tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Japan. J. Hum. Genet., 56, 306-312.
62. Gersting, S.W., Kemter, K.F., Staudigl, M., Messing, D.D., Danecka, M.K., Lagler, F.B., Sommerhoff, C.P., Roscher, A.A. and Muntau, A.C. (2008) Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet., 83, 5-17.
63. Milne, G.W., Nicklaus, M.C., Driscoll, J.S., Wang, S. and Zaharevitz, D. (1994) National Cancer Institute Drug Information System 3D database. J. Chem. Inf. Comput. Sci., 34, 1219-1224.
64. Hawkins, P.C., Skillman, A.G. and Nicholls, A. (2007) Comparison of shape-matching and docking as virtual screening tools. J. Med. Chem., 50, 74-82.
65. Kirchmair, J., Distinto, S., Markt, P., Schuster, D., Spitzer, G.M., Liedl, K.R. and Wolber, G. (2009) How to optimize shape-based virtual screening: choosing the right query and including chemical information. J. Chem. Inf. Model., 49, 678-692.
66. Wolber, G., Dornhofer, A.A. and Langer, T. (2006) Efficient overlay of small organic molecules using 3D pharmacophores. J. Comput. Aided Mol. Des., 20, 773-788.
67. Wolber, G. and Langer, T. (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 45, 160-169.
68. Perspicace, S., Banner, D., Benz, J., Muller, F., Schlatter, D. and Huber, W. (2009) Fragment-based screening using surface plasmon resonance technology. J. Biomol. Screen., 14, 337-349.
69. Lutke-Eversloh, T. and Stephanopoulos, G. (2007) A semi-quantitative high-throughput screening method for microbial L-tyrosine production in microtiter plates. J. Ind. Microbiol. Biotechnol., 34, 807-811.
70. Leijssen, D.P. and Elia, M. (1996) Recovery of 13CO2 and 14CO2 in human bicarbonate studies: a critical review with original data. Clin. Sci. (Lond.), 91, 665-677.